Effect of Panax Ginseng on the Cognitive Performance in Alzheimer’s Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00391833
Recruitment Status : Completed
First Posted : October 24, 2006
Last Update Posted : October 24, 2006
Information provided by:
Seoul National University Hospital

Brief Summary:
We investigate the clinical efficacy of Panax ginseng in Alzheimer’s disease (AD).

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Memory Decline Drug: Panax Ginseng Phase 1 Phase 2

Detailed Description:

Alzheimer’s disease (AD) is characterized by a progressive decline of memory and intellectual abilities, interfering activity in daily living, the overall quality of life, and ultimately leads to death. Although pharmacologic treatments are currently approved for treating mild- to moderate AD using acetylcholinesterase inhibitors (ACEI) or memantine, the NMDA antagonist, for the advanced stage of AD, the therapeutic efficacies need to be further improved.

For millennia, ginseng or its components have been used to treat medical conditions, and the pharmacologic effects have been demonstrated in cardiovascular, endocrine and immune system (Attele et al., 1999). In means of memory and learning, a number of studies suggested that ginseng can attenuate learning deficits of damaged or ageing brains in rodent models (Kennedy et al., 2003; Zhao and McDaniel, 1998; Nitta et al., 1995). In studies with human healthy participants, correspondently, both acute and chronic dosage of ginseng increased the cognitive performance (Kennedy et al., 2001; Kennedy et al., 2003; D’Angelo et al., 1986; Sorensen and Sonne, 1996).

In this study, we we will investigate the contribution of ginseng treatment in increasing the cognitive improvement of AD patients. In addition, we will test various bio-markers and hematopoietic progenitor cell count in those included patients using their blood samples. Patients with AD as well as memory decline will be included

Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : April 2004
Estimated Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Cognitive performances monitored by MMSE and Alzheimer’s disease assessment scales.
  2. Biomarkers including hematopoietic progenitor cell count.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 83 Years   (Adult, Senior)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Alzheimer's disease

Exclusion Criteria:

  • other neurologic disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00391833

Sponsors and Collaborators
Seoul National University Hospital
Study Chair: Manho Kim, MD, PhD Department of Neurology, Seoul National University Hospital

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00391833     History of Changes
Other Study ID Numbers: ginseng-AD
First Posted: October 24, 2006    Key Record Dates
Last Update Posted: October 24, 2006
Last Verified: October 2006

Keywords provided by Seoul National University Hospital:
Alzheimer's disease, Ginseng, CD34

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders